Zhongmou Therapeutics
Clinical trials sponsored by Zhongmou Therapeutics, explained in plain language.
Upcoming readouts
Trials from this sponsor expected to report results within the next 12 months.
- New color vision test could help people with severe vision loss Results expected Jun 2027 (estimated)
-
Gene therapy injection aims to halt blinding eye disease
Disease control Not yet recruitingThis early-stage trial tests a gene therapy called AGX-08 for geographic atrophy, an advanced form of age-related macular degeneration that causes vision loss. The study will involve 24 people aged 50 and older, each receiving a single injection into one eye. The main goal is to …
Early phase 1 • Sponsor: Zhongmou Therapeutics • Aim: Disease control
Last updated Aug 02, 2026 00:00 UTC
-
Gene therapy injection aims to save sight in rare eye disease
Disease control Not yet recruitingThis early-stage trial tests a single injection of ZM-02, a gene therapy, in 21 people aged 6 to 60 with advanced retinitis pigmentosa, a genetic condition that causes progressive vision loss. Participants are randomly assigned to receive either a low or high dose of ZM-02 or a s…
Phase 1/2 • Sponsor: Zhongmou Therapeutics • Aim: Disease control
Last updated Jun 27, 2026 12:06 UTC